Abstract 3911
Background
A decrease in tumor metabolic activity have been shown to be an early indicator of treatment effectiveness for breast cancer.
Methods
We reviewed the records of patients enrolled to the prospective study of prediction of preoperative chemotherapy response (MILESTONE-BreastPred). In the whole group PET/CT was used as an initial method of staging and as response assessment after 1st cycle of chemotherapy. We analysed data of 425 patients, 19.8% TNBC, 12.2% nonluminal HER2-positive and 68% luminal cancers. 88% of patients were stage II or III. pCR rate was 24.8% (ypT0/is ypN0). 31.1% of patients showed progressive disease during follow-up. The aim of the study was to assess the clinical utility of various cut-offs of SUVmax decrease to predict both pCR and disease relapse.
Results
We analysed SUVmax decrease cut-off of 20%, 30%, 40%, 50 and 60%. For pCR prediction, the sensititivity was above 50% for cut-offs 20%-40%, while specificity exceeded 50% for cut-off values 40-60%. In the whole range of cut-offs, there was highly statistically significant difference in pCR rate between low and high SUVmax decrease (p < 0.001). Cut-off of 40% was chosen, providing optimal trade-off between sensitivity and specificity with positive likelihood ratio 1.89, negative likelihood ratio 0.49, PPV 38.4% and PPV 86.0%. Prediction of disease relapse based on 1st cycle SUVmax decrease was more challenging, with sensitivity above 50% for cut-offs 20-30% and specificity above 50% for cut-offs 40-60%. For cut-off 40% the difference in disease relapse between groups was closest to the limit of statistical significance (p = 0.085) and provided PLR 0.81, NLR 1.17, PPV 26.6% and NPV 65.6%.
Conclusions
Prediction of pCR by 1st cycle SUVmax decrease was feasible, with good balance of specificity and sensitivity for cut-off 40%. This cut-off provides the most prominent, although not significant in this analysis, association with the risk of disease relapse. The study was supported by the Polish National Center of Research and Development MILESTONE project–Molecular diagnostics and imaging in individualized therapy for breast, thyroid and prostate cancer, grant no.STRATEGMED2/267398/4/NCBR/2015.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
The authors.
Funding
The study was supported by the Polish National Center of Research and Development MILESTONE project – Molecular diagnostics and imaging in individualized therapy for breast, thyroid and prostate cancer, grant no. STRATEGMED 2/267398/4/NCBR/2015.
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
5812 - Correlation between the density of tumor-infiltrating lymphocytes, immune cell subsets in tumor stroma and response to systemic therapy in breast cancer
Presenter: Cvetka Grasic Kuhar
Session: Poster Display session 2
Resources:
Abstract
4734 - BRCA1/2 Testing in HER2- Advanced Breast Cancer (ABC): Results from the European Component of a Multi-Country Real World Study
Presenter: Michael Patrick Lux
Session: Poster Display session 2
Resources:
Abstract
1686 - In vitro and in vivo rescue of resistance to BET inhibitors by targeting PLK1 in triple negative breast cancer.
Presenter: Cristina Nieto-jiménez
Session: Poster Display session 2
Resources:
Abstract
5020 - Neoadjuvant endocrine therapy in combination with melatonin and metformin in locally advanced breast cancer
Presenter: Tatiana Semiglazova
Session: Poster Display session 2
Resources:
Abstract
5082 - Melatonin and metformin in neoadjuvant chemotherapy in locally advanced breast cancer
Presenter: Tatiana Semiglazova
Session: Poster Display session 2
Resources:
Abstract
2642 - Patient-tailored tamoxifen dosing based on an increased quantitative understanding of its complex pharmacokinetics: A novel integrative modelling approach
Presenter: Anna Mueller-Schoell
Session: Poster Display session 2
Resources:
Abstract
2461 - Lack of benefit of neoadjuvant pertuzumab in high risk HER2 positive breast cancer. A retrospective case-control study of 355 cases with biomarker analysis.
Presenter: Manuela Tiako Meyo
Session: Poster Display session 2
Resources:
Abstract
4776 - Targeting CDCA3 to improve chemotherapy response in triple-negative breast cancer patients
Presenter: Kenneth O'Byrne
Session: Poster Display session 2
Resources:
Abstract
1674 - Activity of BET-proteolysis targeting chimeric (PROTAC) compounds in triple negative breast cancer
Presenter: María Del Mar Noblejas López
Session: Poster Display session 2
Resources:
Abstract
5629 - Outcome of triple negative inflammatory breast cancers (TNIBC) treated with dose dense neoadjuvant epirubicin cyclophosphmide, prognostic impact of pre and post neoadjuvant chemotherapy (NAC) tumor infiltrating lymphocytes (TIL) and post NAC lymphovascular invasion
Presenter: Luca Campedel
Session: Poster Display session 2
Resources:
Abstract